TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17127027

Group type: EXPERIMENTAL
Intervention: Test formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 12
Study: 15309009

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2231
Study: 11593835

Group type: EXPERIMENTAL
Intervention: Tailored implementation strategies for GPs
Number of subjects: 192

Group type: COMPARATOR
Intervention: Dissemination alone (control group)
Number of subjects: 192
Study: 9181425

Group type: EXPERIMENTAL
Intervention: Quality assessment tool developed using Delphi technique
Number of subjects: 8

Group type: COMPARATOR
Intervention: Quality assessment tool
Number of subjects: 8
Study: 7940710

Group type: EXPERIMENTAL
Intervention: High dose oral acyclovir (800 mg 4 times a day) for 3 months
Number of subjects: 143

Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg twice a day for 14 days) followed by high dose oral acyclovir for 3 months
Number of subjects: 143
Study: 3207788

Group type: EXPERIMENTAL
Intervention: Stimulus categorization (length of letter strings)
Number of subjects: 7
Study: 30238292

Group type: EXPERIMENTAL
Intervention: Pre-incarceration services utilization
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Health services utilization
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: High rates of health services use
Number of subjects: 168
Study: 28505217

Group type: EXPERIMENTAL
Intervention: Combined patient decision aid and patient navigation
Number of subjects: 265

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 265
Study: 26081985

Group type: EXPERIMENTAL
Intervention: AmBisome 10 mg/kg day one (single dose)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: AmBisome 10 mg/kg day one and AmBisome 5 mg/kg day three (two doses)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: AmBisome 10 mg/kg day one, and AmBisome 5 mg/kg days three and seven (three doses)
Number of subjects: 160

Group type: COMPARATOR
Intervention: AmBisome 3 mg/kg/d for 14 days
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Shortest course AmBisome regimen found to be non‐inferior in terms of EFA to the 14‐day control arm in STEP 1
Number of subjects: 160
Study: 24083734

Group type: EXPERIMENTAL
Intervention: Pyogenic liver abscess (PLA)
Number of subjects: 1987

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1987

Group type: EXPERIMENTAL
Intervention: PLA group
Number of subjects: 1987

Group type: EXPERIMENTAL
Intervention: PLA group within the first year after diagnosis
Number of subjects: 1987

Group type: EXPERIMENTAL
Intervention: PLA group more than one year after diagnosis
Number of subjects: 1987
Study: 21214352

Group type: EXPERIMENTAL
Intervention: Cooling collar (CC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No collar (NC)
Number of subjects: 8
Study: 18442788

Group type: EXPERIMENTAL
Intervention: Dzherelo (50 drops twice per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (ATT: Isoniazid, Rimfapicin, Pyrazinamide, Streptomycin, Ethambutol)
Number of subjects: 40
Study: 17305200

Group type: EXPERIMENTAL
Intervention: Cognitive career-oriented group counseling
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nontreated group (control)
Number of subjects: 80
Study: 14700111

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg 30-45 minutes preoperatively
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Placebo 30-45 minutes preoperatively and diclofenac 100 mg at induction
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo 30-45 minutes preoperatively
Number of subjects: 157
Study: 10906499

Group type: EXPERIMENTAL
Intervention: Cyclessa (desogestrel/ethinyl estradiol)
Number of subjects: 4200

Group type: COMPARATOR
Intervention: Ortho‐Novum 7/7/7 (norethindrone/ethinyl estradiol)
Number of subjects: 4200
Study: 8796933

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1421679

Group type: EXPERIMENTAL
Intervention: Velnacrine 450 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Velnacrine 300 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Velnacrine 225 mg/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Velnacrine 25 mg, 50 mg, 100 mg (twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3900296

Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30419103

Group type: EXPERIMENTAL
Intervention: Comprehensive 3-month program for long-term self-management of COPD delivered by trained COPD nurses (n=120)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (n=120) including transition support for 30 days after discharge
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Comprehensive 3-month program for long-term self-management of COPD
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 26809849

Group type: EXPERIMENTAL
Intervention: Nicotine patches (5-week supply: 3 weeks of 21 mg, 1 week of 14 mg, 1 week of 7 mg)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no nicotine patches or other intervention)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Nicotine patches (5-week supply)
Number of subjects: 1000
Study: 26222318

Group type: EXPERIMENTAL
Intervention: Linaclotide 145 μg
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Linaclotide 290 μg
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 24146767

Group type: EXPERIMENTAL
Intervention: IMPLEMENT intervention (active implementation of guideline recommendations plus standard dissemination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dissemination alone
Number of subjects: 0
Study: 20952160

Group type: EXPERIMENTAL
Intervention: Surgical release by fasciectomy or dermofasciectomy
Number of subjects: 154
Study: 18469422

Group type: EXPERIMENTAL
Intervention: Telephone call reminder for re-enrollment
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Usual care (postcard reminder)
Number of subjects: 1209
Study: 16532436

Group type: EXPERIMENTAL
Intervention: TPZ, cisplatin, and 5-fluorouracil (5-FU)
Number of subjects: 62

Group type: COMPARATOR
Intervention: cisplatin and 5-fluorouracil (5-FU) without TPZ
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 62
Study: 15228820

Group type: EXPERIMENTAL
Intervention: Pre-anesthesia outpatient consultation clinic 1 to 2 weeks prior to surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pre-anesthetic assessment on the evening before surgery
Number of subjects: 40
Study: 11199703

Group type: EXPERIMENTAL
Intervention: Chlorine dioxide-containing mouthrinse
Number of subjects: 31

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 31
Study: 9091253

Group type: EXPERIMENTAL
Intervention: 3-D FSE imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-D imaging
Number of subjects: 0
Study: 8155115

Group type: EXPERIMENTAL
Intervention: Laser scalpel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional scalpel
Number of subjects: 40
Study: 3524474

Group type: EXPERIMENTAL
Intervention: PEP mask with forced expiratory coughing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 0
Study: 28526995

Group type: EXPERIMENTAL
Intervention: Two cycles of PRGF-Endoret (TC group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: One cycle of PRGF-Endoret (OC group)
Number of subjects: 90
Study: 27903339

Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic management group (G group, n=45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Experience anesthesia group (group E, n=45)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic management group (G group)
Number of subjects: 90
Study: 24794140

Group type: EXPERIMENTAL
Intervention: Detectable cTnI levels at both time points (≥0.01 µg/L)
Number of subjects: 2514

Group type: EXPERIMENTAL
Intervention: Persistent elevation of either or both cardiac biomarkers (cTnI and NT-proBNP) at baseline and 3 months
Number of subjects: 2514

Group type: EXPERIMENTAL
Intervention: Repeated measurements of both cardiac biomarkers simultaneously
Number of subjects: 2514
Study: 23061619

Group type: EXPERIMENTAL
Intervention: Monthly feedback on ventilator care bundle (VCB) compliance
Number of subjects: 2
Study: 20102886

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 535
Study: 18612730

Group type: EXPERIMENTAL
Intervention: Training the Eye: Improving the Art of Physical Diagnosis (eight paired sessions of art observation exercises)
Number of subjects: 24
Study: 15785019

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 232

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 232
Study: 11336939

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 33
Study: 9210542

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure at 30 cm H2O
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline airway pressure (0 cm H2O)
Number of subjects: 15
Study: 7963789

Group type: EXPERIMENTAL
Intervention: Codeine Contin 100 mg every 12 hr
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Codeine Contin 200 mg every 12 hr
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Codeine Contin 300 mg every 12 hr
Number of subjects: 24

Group type: COMPARATOR
Intervention: Acetaminophen plus codeine (600 mg/60 mg) every 6 hr
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Codeine Contin 150 mg every 12 hr
Number of subjects: 24
Study: 3039842

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg per day)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 205
Study: 29750977

Group type: EXPERIMENTAL
Intervention: HD-tDCS (1.5 mA for 25 minutes per day for two weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: HD-tDCS
Number of subjects: 31
Study: 27829573

Group type: COMPARATOR
Intervention: Usual care delivered by a local rural Nurse Practitioner (NP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local NP and an urban-based Physical Therapist (PT) joining via telehealth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face-to-face services by a PT traveling to the community
Number of subjects: 0
Study: 23814135

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 21220619

Group type: EXPERIMENTAL
Intervention: 0.7-mg DEX implant
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 0.35-mg DEX implant
Number of subjects: 229

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 229
Study: 19321584

Group type: EXPERIMENTAL
Intervention: High milk consumption (4 x 236 mL/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low milk consumption (1 x 236 mL/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High milk consumption
Number of subjects: 0
Study: 17042662

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg BID orally, 4 doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard intravenous fluid hydration
Number of subjects: 20
Study: 12772815

Group type: EXPERIMENTAL
Intervention: Brimonidine Purite and bimatoprost (brimP/bim)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Timolol gel-forming solution and latanoprost (tim/latan)
Number of subjects: 28
Study: 10942479

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9425384

Group type: EXPERIMENTAL
Intervention: Nasal prongs
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nasopharyngeal catheters
Number of subjects: 121
Study: 8218507

Group type: EXPERIMENTAL
Intervention: Relaxation training (10 sessions over 8 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Symptom Monitoring (control group)
Number of subjects: 16
Study: 3067105

Group type: EXPERIMENTAL
Intervention: Prostacyclin sodium (2.5-5.0 ng/kg/min) administered intravenously once daily during 2 weeks in 6-hour infusions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (glycine buffer) administered intravenously once daily during 2 weeks in 6-hour infusions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prostacyclin sodium
Number of subjects: 30
Study: 28754504

Group type: EXPERIMENTAL
Intervention: Health messaging intervention focused on provider communication about vaccination for HPV vaccine.
Number of subjects: 2476

Group type: EXPERIMENTAL
Intervention: Health messaging intervention focused on provider communication about vaccination for influenza vaccine.
Number of subjects: 2476
Study: 28494175

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (supportive treatments + plasmapheresis)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Supportive treatments (Control group)
Number of subjects: 29
Study: 26241316

Group type: EXPERIMENTAL
Intervention: Approach avoid training (real)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Approach avoid training (sham)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: General identity training (real)
Number of subjects: 588

Group type: COMPARATOR
Intervention: General identity training (sham)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Personalized identity training (real)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Personalized identity training (sham)
Number of subjects: 588
Study: 23590163

Group type: EXPERIMENTAL
Intervention: Viewing nature scenes (composed of trees, grass, fields)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viewing built environments (composed of man‐made, urban scenes lacking natural characteristics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viewing nature scenes
Number of subjects: 0
Study: 21420417

Group type: EXPERIMENTAL
Intervention: ACWY-TT co-administered with DTaP-HBV-IPV/Hib
Number of subjects: 793
Study: 19294861

Group type: EXPERIMENTAL
Intervention: Chinese medicinal formulae with immune regulation effects (group one)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Random Chinese medicinal formulae (control group)
Number of subjects: 60
Study: 20153489

Group type: EXPERIMENTAL
Intervention: Exercise intervention (7-week endurance-type exercise at 65%-80% of maximum heart rate)
Number of subjects: 70
Study: 16048220

Group type: EXPERIMENTAL
Intervention: Urgotul dressing
Number of subjects: 91

Group type: COMPARATOR
Intervention: DuoDERM E dressing
Number of subjects: 91
Study: 12351482

Group type: EXPERIMENTAL
Intervention: IGFBP-1
Number of subjects: 239
Study: 9842243

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 31

Group type: COMPARATOR
Intervention: Amikacin/metronidazole combination
Number of subjects: 31
Study: 8018396

Group type: EXPERIMENTAL
Intervention: Domperidone 60 mg suppositories every 4 h
Number of subjects: 136

Group type: COMPARATOR
Intervention: Prochlorperazine 25 mg suppositories every 4 h
Number of subjects: 136
Study: 2904464

Group type: EXPERIMENTAL
Intervention: Penicillin G and sulphadiazine for 5 days postoperatively
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: Penicillin for 5 days postoperatively
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: Penicillin and sulphadiazine for 5 days postoperatively
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: Erythromycin for 5 days postoperatively
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: Penicillin for 5 days preoperatively
Number of subjects: 3180

Group type: COMPARATOR
Intervention: Uncontrolled studies with no specific intervention
Number of subjects: 3180
Study: 28816881

Group type: EXPERIMENTAL
Intervention: Shikani optical stylet (SOS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flexible fiberscope
Number of subjects: 60
Study: 27530232

Group type: EXPERIMENTAL
Intervention: Furosemide (intravenous)
Number of subjects: 30
Study: 25288038

Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hyperoxia (InHO) for 4 hours daily for 2 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hyperoxia (InHO)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (breathing air via non-rebreathing reservoir mask)
Number of subjects: 62
Study: 23960180

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance for 8 months, once every 2 months for a total of four doses
Number of subjects: 202

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 202
Study: 21968665

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (ABO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA (ONA)
Number of subjects: 20
Study: 18192898

Group type: EXPERIMENTAL
Intervention: 15-mg NRT transdermal patch for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active treatment (NRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NRT transdermal patch
Number of subjects: 0
Study: 16582058

Group type: EXPERIMENTAL
Intervention: Brief therapy
Number of subjects: 702

Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 702
Study: 12642264

Group type: EXPERIMENTAL
Intervention: Low-energy shock wave treatment (3 applications of 2100 impulses)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 45
Study: 10955372

Group type: EXPERIMENTAL
Intervention: Celiprolol (0.30 mg/kg IV)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Atenolol (0.15 mg/kg IV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8805958

Group type: EXPERIMENTAL
Intervention: Supervised walking program
Number of subjects: 21
Study: 1624927

Group type: EXPERIMENTAL
Intervention: Carbamazepine (800 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbamazepine (800 mg) and 400 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 20
Study: 6526589

Group type: EXPERIMENTAL
Intervention: Low sensitivity feedback
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High sensitivity feedback
Number of subjects: 90

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 90
Study: 29877227

Group type: EXPERIMENTAL
Intervention: Paprika xanthophylls (9 mg) administered daily for 5 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo administered daily for 5 weeks
Number of subjects: 46
Study: 26523330

Group type: EXPERIMENTAL
Intervention: 0.2 mg triptorelin
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 0.3 mg triptorelin
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 0.4 mg triptorelin
Number of subjects: 165
Study: 23668822

Group type: EXPERIMENTAL
Intervention: Self-discrepancy monitoring (SDM) after recalling a positive memory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (observing feelings after recalling a positive memory)
Number of subjects: 0
Study: 23539724

Group type: EXPERIMENTAL
Intervention: 1 μg ACTH(1-24) intravenous stimulation test
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 250 μg ACTH(1-24) intramuscular stimulation test
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Free cortisol measurement
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Total cortisol measurement by immunoassay and LCMS
Number of subjects: 81
Study: 20065185

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/d plus risedronate 35 mg/wk orally (A + R)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Anastrozole 1 mg/d plus placebo (A + P)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Anastrozole (A) alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/d plus risedronate 35 mg/wk orally (A + R) in high-risk group
Number of subjects: 3
Study: 18719507

Group type: EXPERIMENTAL
Intervention: Plastic stents
Number of subjects: 62

Group type: COMPARATOR
Intervention: Metallic stents
Number of subjects: 62
Study: 17080224

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Number of subjects: 206
Study: 15570651

Group type: EXPERIMENTAL
Intervention: tramadol/APAP (tramadol 37.5 mg/acetaminophen 325 mg)
Number of subjects: 338

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 338
Study: 11305854

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 42
Study: 9230863

Group type: EXPERIMENTAL
Intervention: Preincisional bupivacaine infiltration (40 mL of 0.25% bupivacaine 5 minutes before incision)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Postincisional bupivacaine infiltration (40 mL of 0.25% bupivacaine immediately after approximation of the fascia)
Number of subjects: 112
Study: 10132454

Group type: EXPERIMENTAL
Intervention: Consensus guidelines agreed between GPs and specialists
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no guidelines)
Number of subjects: 179
Study: 3028458

Group type: EXPERIMENTAL
Intervention: 10 mg ramipril
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6
Study: 29708589

Group type: EXPERIMENTAL
Intervention: Phenylephrine (α1-agonist) during exercise trials
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (α2-agonist) during exercise trials
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Resting and high flow trials with α1 and α2 agonists
Number of subjects: 16
Study: 27779192

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied over M1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over DLPFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS over M1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS over DLPFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 0
Study: 25703911

Group type: COMPARATOR
Intervention: Control group (no anesthesia)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: INB (iliohypogastric nerve block)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intrarectal prilocaine‐lidocaine cream application
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: INB + intrarectal prilocaine‐lidocaine cream application (combined group)
Number of subjects: 59